Keyword: Third Rock Ventures
As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.
Fresh off Tilos Therapeutics’ $773 million sale to Merck, Barbara Fox is taking the helm of another Cambridge-based company: Rheos Medicines.
Mary Rozenman, Ph.D., signs on from Aimmune as Insitro's CFO and chief business officer and Pfizer veteran Keith James, Ph.D., joins as SVP of drug discovery.
Celsius’ new deal with Janssen is a win-win—it will feed Celsius' drug discovery and help Janssen work on a treatment for ulcerative colitis.
The investment vehicle, the largest ever raised by Third Rock, will support investments in 10 to 12 companies.
Thrive debuted with $110 million, liquid biopsy technology from Johns Hopkins and Third Rock's Steve Kafka at the helm to catch cancer earlier.
Relay's $400 million series C round came just two years after its official launch and relatively modest $57 million A round.
Now, Insitro is ready to share a little more—starting with a Gilead partnership worth $15 million upfront, but that could total more than $1 billion.
Maze Therapeutics aims to understand how some genes provide protection against disease so that they can be targeted with drugs.
Relay Therapeutics reeled in a $400 million round to boost its platform technology and discovery efforts, build its pipeline and get into the clinic.